



# Qlife's new filtration unit significantly broadens the market for the Ego platform

**Qlife has developed a new, small, and disposable filtration unit able to filtrate plasma from whole blood. The filtration unit, EgoCollect, will be an integral feature of the Ego platform making it more versatile and ideal for decentralized settings. A patent application for EgoCollect has recently been filed. The next step is to incorporate EgoCollect in the development of the PKU test in accordance with IVDR.**

Qlife's scientific team has completed the development of a blood-to-plasma filtration unit for blood-based biomarker testing. The Ego capsule already integrates all reagents and with the new filtration unit instead of adding whole blood into the capsule now plasma is entered, and the test is executed in the device accordingly. In short, the filtration unit is making the Ego platform more versatile as it now can be used for testing plasma in addition to whole blood.

- New biomarkers: The range of biomarkers the Ego platform can detect increases significantly since many protein-based assays should be measured in plasma to maintain the clinical-grade level
- Accuracy: EgoCollect will help the Ego platform produce even more accurate tests due to testing in plasma instead of whole blood
- Faster and cost-effective development: Future biomarker tests will be easier and more cost-effective to develop since increased accuracy means less risk and faster validation.

"EgoCollect makes the Ego platform more competitive - in terms of use in decentralized settings. As of today, we are not aware of a similar or as powerful filtration unit for point-of-care platforms that target a variety of biomarker tests. By incorporating this technology in future biomarker tests, we are eager to explore the new opportunities this innovation opens for us. It will significantly accelerate the development of our protein-based tests", says Thomas Warthoe, CEO of Qlife.

EgoCollect will be an integral feature of the Ego platform, and as such included in the regulatory process of each test that requires plasma filtration. A patent application for EgoCollect has just been filed and covers the composition and the function of the unit. Moving forward, EgoCollect will be featured in the PKU test which Qlife is currently developing in accordance with IVDR.

This is how the EgoCollect works:

As the graphics in the document shows (<https://www.egoo.health/blood-to-plasma>), the EgoCollect consists of a small filtering unit where a drop of blood is collected and filtered in several steps inside the unit. A certain amount of plasma is then transferred to a detachable collector that is detached from the EgoCollect unit and inserted into the test capsule of the Ego platform. The capsule is then inserted into the Ego device and test results produced.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was

submitted for publication, through the agency of the contact person, on 12-05-2022 09:00 CET.

**For more information please contact:**

Thomas Warthoe, CEO  
tw@egoo.health  
+45 21 63 35 34

**Qlife** is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on [Egoo.health](https://egoo.health), [Qlifeholding.com](https://qlifeholding.com) or follow us on [LinkedIn](https://www.linkedin.com/company/qlife).